{
    "clinical_study": {
        "@rank": "14871", 
        "arm_group": [
            {
                "arm_group_label": "treatment 1", 
                "arm_group_type": "Experimental", 
                "description": "FSH-GEX(TM)"
            }, 
            {
                "arm_group_label": "treatment 2", 
                "arm_group_type": "Experimental", 
                "description": "FSH-GEX(TM)"
            }, 
            {
                "arm_group_label": "treatment 3", 
                "arm_group_type": "Experimental", 
                "description": "FSH-GEX(TM)"
            }, 
            {
                "arm_group_label": "treatment 4", 
                "arm_group_type": "Experimental", 
                "description": "FSH-GEX(TM)"
            }, 
            {
                "arm_group_label": "treatment 5", 
                "arm_group_type": "Experimental", 
                "description": "FSH-GEX(TM)"
            }, 
            {
                "arm_group_label": "treatment 6", 
                "arm_group_type": "Active Comparator", 
                "description": "Gonal-f(R)"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the current study is the determination of the recommended standard treatment dose\n      of FSH-GEX(TM) in women undergoing ICSI (intracytoplasmic sperm injection) treatment as\n      assessed by follicle growth."
        }, 
        "brief_title": "Efficacy and Safety of FSH-GEX\u2122 in Comparison With 150 IU Gonal-f\u00ae", 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female patient for whom ICSI treatment is justified\n\n          -  serum follicle-stimulating hormone concentration\n\n          -  Anti-mullerian hormone concentration\n\n          -  Antral follicle count\n\n          -  Body mass index and body weight\n\n          -  Presence of both ovaries\n\n          -  Regular spontaneous cycles between 21 and 35 days in length\n\n          -  Normal uterine cavity as assessed by transvaginal sonography at Screening\n\n          -  Willing and able to comply with the protocol\n\n          -  Willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients who had more than two unsuccessful previous assisted reproduction technology\n             cycles before inclusion into the study\n\n          -  Previous poor responders\n\n          -  Patients with previous hyperstimulation syndrome or cycle cancellation because of\n             imminent hyperstimulation syndrome\n\n          -  Patients with a history of or current polycystic ovarian morphology syndrome\n\n          -  Patients with a history of or current endometriosis III or IV\n\n          -  Presence of ovarian cyst at Screening\n\n          -  Any contraindication to becoming pregnant\n\n          -  History of \u2265 3 clinical or preclinical miscarriages\n\n          -  abnormal cervical smear, Papanicolaou [PAP] score \u2265 3\n\n          -  Any history of malignant cancer other than in situ breast or skin cancer requiring\n             local excision\n\n          -  Any endocrine abnormalities requiring treatment\n\n          -  Any clinically significant systematic disease\n\n          -  Any known infection with human immunodeficiency virus, hepatitis B or C\n\n          -  History of thrombosis or other risk factors including any coagulation abnormality\n             leading to an increased risk of clotting\n\n          -  Family history of genetic risk factors concerning pregnancy or birth\n\n          -  Use of concomitant medication, which in the opinion of the investigator might\n             interfere with ICSI preparation procedures\n\n          -  Active smoking\n\n          -  Any active substance abuse of drugs, medications or alcohol within the last five\n             years\n\n          -  Patients in an institution by official or court order\n\n          -  Patients who are unable or unwilling to provide informed consent\n\n          -  Any participation in another clinical trial within the last 60 days before\n             randomisation\n\n          -  Previous FSH-GEX\u2122 administration.\n\n          -  Known hypersensitivity to any component of the investigational and non\n             investigational products used in this study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "37 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794208", 
            "org_study_id": "GEXGP24201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "treatment 1", 
                    "treatment 2", 
                    "treatment 3", 
                    "treatment 4", 
                    "treatment 5"
                ], 
                "intervention_name": "FSH-GEX(TM)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "treatment 6", 
                "intervention_name": "Gonal-f(R)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "in-vitro fertilization", 
            "reproductive disorder"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Investigator"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Investigator"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Hungary"
            ]
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase II, Multicentre, Multinational, Randomised, Assessor-Blind Trial to Investigate the Efficacy and Safety of Various Dosages of FSH-GEX\u2122 in Comparison With 150 IU Gonal-f\u00ae in Women Undergoing ICSI Treatment", 
        "overall_official": {
            "affiliation": "Glycotope GmbH", 
            "last_name": "study director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Hungary: National Institute of Pharmacy", 
                "Germany: Federal Institute for Drugs and Medical Devices"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of follicles on the day of hCG injection after stimulation with follicle stimulating hormone (FSH)", 
            "measure": "number of follicles", 
            "safety_issue": "No", 
            "time_frame": "day of hCG (human chorionic gonadotropin) injection; variable timeframe; up to 4 weeks treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794208"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "follicular response as determined by transvaginal ultrasonography", 
                "measure": "pharmacodynamic effect of FSH following administration by subcutaneous injection", 
                "safety_issue": "No", 
                "time_frame": "every second day up to HCG injection; variable timeframe; up to 4 weeks treatment"
            }, 
            {
                "measure": "number of retrieved cumulus-oocyte-complexes", 
                "safety_issue": "No", 
                "time_frame": "at oocyte retrieval; up to 2 days after hCG injection"
            }, 
            {
                "measure": "number of oocytes retrieved", 
                "safety_issue": "No", 
                "time_frame": "at oocyte retrieval; up to 2 days after hCG injection"
            }, 
            {
                "measure": "number of two pronuclei oocytes", 
                "safety_issue": "No", 
                "time_frame": "one day after oocyte retrieval"
            }, 
            {
                "measure": "biochemical pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "14 to 20 days after last FSH dose"
            }, 
            {
                "measure": "rate of clinical pregnancy", 
                "safety_issue": "No", 
                "time_frame": "approx. 4 to 6 weeks after last FSH dose"
            }, 
            {
                "measure": "Implantation rate", 
                "safety_issue": "No", 
                "time_frame": "approx. 4  - 6 weeks after last FSH dose"
            }, 
            {
                "description": "Estradiol and inhibin B serum levels", 
                "measure": "pharmacodynamic effect of FSH following administration by subcutaneous injection", 
                "safety_issue": "No", 
                "time_frame": "every second day up to HCG injection; variable timeframe; up to 4 weeks treatment"
            }, 
            {
                "measure": "ongoing pregnancy rate and live birth rate", 
                "safety_issue": "No", 
                "time_frame": "post-study observation period of 9 months after hCG stimulation"
            }, 
            {
                "measure": "incidence of adverse events, ovarian hyperstimulation syndrome, anti-drug-antibodies, overall tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 to 6 weeks after last FSH dose"
            }
        ], 
        "source": "Glycotope GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glycotope GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}